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Abstract
The Calcium Sensing Receptor (CaSR) plays a role in calcium homeostasis by sensing minute changes in serum Ca2+ and
modulating secretion of calciotropic hormones. It has been shown in transfected cells that accessory proteins known as
Receptor Activity Modifying Proteins (RAMPs), specifically RAMPs 1 and 3, are required for cell-surface trafficking of the
CaSR. These effects have only been demonstrated in transfected cells, so their physiological relevance is unclear. Here we
explored CaSR/RAMP interactions in detail, and showed that in thyroid human carcinoma cells, RAMP1 is required for
trafficking of the CaSR. Furthermore, we show that normal RAMP1 function is required for intracellular responses to ligands.
Specifically, to confirm earlier studies with tagged constructs, and to provide the additional benefit of quantitative
stoichiometric analysis, we used fluorescence resonance energy transfer to show equal abilities of RAMP1 and 3 to
chaperone CaSR to the cell surface, though RAMP3 interacted more efficiently with the receptor. Furthermore, a higher
fraction of RAMP3 than RAMP1 was observed in CaSR-complexes on the cell-surface, suggesting different ratios of RAMPs to
CaSR. In order to determine relevance of these findings in an endogenous expression system we assessed the effect of
RAMP1 siRNA knock-down in medullary thyroid carcinoma TT cells, (which express RAMP1, but not RAMP3 constitutively)
and measured a significant 50% attenuation of signalling in response to CaSR ligands Cinacalcet and neomycin. Blockade of
RAMP1 using specific antibodies induced a concentration-dependent reduction in CaSR-mediated signalling in response to
Cinacalcet in TT cells, suggesting a novel functional role for RAMP1 in regulation of CaSR signalling in addition to its known
role in receptor trafficking. These data provide evidence that RAMPs traffic the CaSR as higher-level oligomers and play a
role in CaSR signalling even after cell surface localisation has occurred.
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Introduction
The G-protein coupled receptor (GPCR) family is the largest
family of cell-surface receptors in mammals and is involved in
numerous vital functions such as taste, odour, memory, response
to light, and the action of hormones and neurotransmitters [1].
The Calcium Sensing Receptor (CaSR) is a family C GPCR that
binds calcium principally and plays an essential role in systemic
calcium homeostasis [2]. The CaSR is involved in regulation of
parathyroid hormone (PTH) secretion from parathyroid chief cells
[2], and calcitonin secretion from thyroid parafollicular C-cells [3].
PTH has complex physiological functions, increasing serum
calcium by enhancing bone resorption and (through its promotion
of activation of Vitamin D) absorption of calcium from the gut and
reducing renal calcium excretion [4]. Transient high PTH levels
have the opposite effect, mediating increased bone formation by
an as yet poorly understood pharmacological mechanism [5]. In
contrast, calcitonin inhibits the function of bone-resorbing
osteoclasts and reduces urinary calcium excretion[6]. The
importance of CaSR in calcium homeostasis is emphasized by
the pathological conditions of calcium homeostasis caused by
inactivating and activating CaSR mutations such as Familial
Hypocalciuric Hypercalcaemia (FHH), Neonatal Severe Hyper-
parathyroidism (NSHPT) [7,8]; and Autosomal Dominant Hypo-
calcaemia (ADH) [9]. The CaSR is a promiscuous receptor which
binds a variety of natural and synthetic ligands such as the cations,
Ca2+, Mg2+, Gd3+, Zn2+, Ni2+ [2,10,11]; the polyamines, spermine
and spermidine [12]; aminoglycoside antibiotics such as neomycin
[13], phenylalkylamine derivatives including calcimimetics (allo-
steric activators) [14,15] and calcilytics (antagonists) [16]. Follow-
ing activation of the CaSR, downstream signalling is complex and
cell-type dependent. CaSR is shown to couple to more than one
G-protein subtype (Gq, Gi, Gs, G12/13 [17–20]) and to activate
MAPKs such as ERK1/2 [21,22] that elicit different actions based
stimulus and the cell type. It has been demonstrated that in
transfected cells, the CaSR is unable to traffic to the cell
membrane alone [23,24], and that two members of a family of
type-1 trans-membrane proteins known as Receptor Activity
Modifying Proteins (RAMPs 1 and 3) interact with CaSR and
facilitate its localization at the cell surface.
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The RAMPs were discovered in attempts to clone the receptor
for calcitonin gene-related peptide (CGRP) [25]. It was discovered
that the ‘‘CGRP receptor’’ was a heteromer of the calcitonin-like
receptor (CLR) and RAMP1. The CLR forms an adrenomedullin
receptor with either RAMPs 2 or 3 [25], while RAMP association
of the calcitonin receptor forms 3 variants of a receptor for Amylin
[26]. Since then, the roles of RAMPs in regulation of ligand
selectivity and trafficking have become well-established in several
high profile studies. The role for RAMPs in trafficking was
detected first in association with the CLR [25], which like the
CaSR, requires a RAMP for expression at the cell surface [23].
Other receptors are known to traffic with RAMPs (including the
PTH, glucagon, VIP [27], and secretin receptors [28]), but these
are not obligate relationships and those receptors do not require
RAMPs for surface expression. In the case of VPAC1/VIP
receptor, association of RAMP2 leads to an increase in inositol
phosphate hydrolysis [27], showing a direct role of RAMP in
modifying the signalling of the receptor. So far, the only known
family C GPCR partner of RAMPs is the CaSR [23], and no
other functions except for cell surface trafficking of the receptor
have been identified.
The aims of the current study were: 1) to acquire more detailed
information about the CaSR/RAMP interactions during traffick-
ing and cell surface presentation, and 2) to determine whether
CaSR/RAMP interactions in cells naturally expressing endoge-
nous levels have functional relevance.
Here we show, using sensitized FRET and FRET-based
stoichiometry, new data regarding interactions of RAMPs 1 and
3 with the CaSR. Additionally, we show that in human medullary
thyroid carcinoma cells (TT), a significant reduction in the
signalling of the CaSR when RAMP1 is knocked down or blocked
with a RAMP1 antibody.
Methods
Cell lines
COS-7 and TT cell lines (ATCC) were maintained in T-
175 cm2 flasks (Nunclon, Thermo scientific) in complete DMEM
and F-12K medium (GIBCO, Paisley) respectively, at 37uC in 5%
CO2 incubator. The complete medium contained 10% heat
inactivated Fetal Calf Serum (FCS, GIBCO Paisley), 1 mM
Sodium Pyruvate (Sigma-Aldrich) and 1% penicillin and strepto-
mycin (Sigma-Aldrich). Thereafter, the media were changed twice
a week until the cells were confluent. Cells used in experiments
were in their exponential growth phase.
Preparation of constructs for FRET and COS-7 cell
transfection
Citrine or Cerulean cDNAs were engineered into a pcDNA3.1
vector (Invitrogen) between the Not1 and Xho1 restriction enzyme
sites. RAMPs and CaSR were engineered into pcDNA3.1
Cerulean and Citrine vectors respectively excluding their stop
codons, between the Kpn1 and Not1, and HindIII and Not1
restriction enzyme sites, so that the fluorophores were present at
the C-terminal of RAMP/CaSR. As a negative control, pcDNA
3.1 containing Citrine alone were co-transfected with a pcDNA3.1
RAMP Cerulean vector. As a positive control, we created a
pcDNA3.1 vector containing a Cerulean cDNA fusion construct
followed by 18 amino acid linker sequence and then Citrine
cDNA.
COS-7 cells were grown to confluency and harvested using
trypsin/EDTA (Sigma), washed with PBS, and resuspended in
electroporation buffer (composition [mM] 20 HEPES, 135 KCl, 2
MgCl2, 2 ATP, 5 glutathione, 0.5% Ficoll 400 adjusted to pH 7.6
using KOH) at a concentration of ,3.5– 4 million cells into 4 mm
gap electroporation cuvettes (York Biosciences, UK) and the
required concentration of DNA was added (10mg receptor, 15mg
RAMP constructs). The cells were then electroporated at 0.25 kV
and 960 mF using a Gene Pulser (Biorad) and cultured for 72 hr in
35 mm glass-bottom plated (Ibidi, Mu¨nchen) after which they
were fixed with 4% PFA and mounted with Mowiol.
FRET imaging
Images were captured using a Zeiss Plan apo 636/1.4 oil
immersion lens on a Zeiss LSM 510 inverted laser scanning
confocal fluorescence microscope fitted with an argon laser at
room temperature. Confocal images of the fluorescent proteins
were acquired using an argon laser together with an HFT458/
514 nm dichroic, a NFT515 nm beam splitter, pin hole set to
496mm, detector gain 550 and individually as a separate channel
under the following conditions: Cerulean was excited using the
458 nm laser line with a 100% laser intensity and a band pass
BP480–520 emission filter; Citrine was excited using the 514 nm
laser line attenuated to 20% laser intensity and a band pass
BP535–590 emission filter; FRET was excited using the 458 nm
laser line with a 100% laser intensity and a BP480–520 emission
filter. All fluorescence channels were scanned and the collected
together, line by line with a mean of 1.
Cerulean and Citrine fluorescence bleed-through into the
FRET channel were calculated using FRET and co-localization
analyser plugin for ImageJ [29]. NFRET calculations for FRET
efficiency for sensitized emission were done using pixel-by-pixel
analysis by PixFRET plugin for ImageJ [30]. The threshold for
pixel intensity to be included in analysis was set to 1.5 times the
background intensity. The following equation was used to
calculate FRET efficiency:
NFRET~
FRET{½CFP|(CFPBT){½YFP|(YFPBT)ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(CFP|YFP)
p
BT= bleed through
The correction factors calculated were: b (proportionality
constant relating donor fluorescence detected at the acceptor
emission relative to that detected at the donor emission): 0.31, a
(proportionality constant relating acceptor fluorescence at the
acceptor excitation to the donor excitation): 0.126, c (ratio of the
extinction coefficient of the acceptor to the donor at the donor
excitation): 0.3, j (proportionality constant relating the sensitized
acceptor emission to the decrease in donor fluorescence due to
FRET): 0.2.
Cell surface FRET was separated from whole cell FRET by
constructing a series of 50-pixel diameter dots around the cell
surface of the raw acceptor image using the selection tool of Image
J. Each dot was taken as a ROI and the combined ROIs for each
image were used to calculate mean membrane NFRET and
stoichiometry values. All FRET-based stoichiometric analysis was
performed as previously described [31] using ImageJ software.
Knock-down of RAMP1 mRNA expression in TT cells
using siRNA
In order to knock-down RAMP1 mRNA expression, TT cells
were transfected with RAMP1 siRNA or negative control
scrambled (sc) siRNA using electroporation. The RAMP1 and sc
siRNA sequences were the same as used successfully by Bouschet
et al [23]. Approximately 1.5 million TT cells were transfected with
1.5mg of RAMP1 or sc siRNA in 0.4 ml final volume at 960mF and
RAMP1 Is Involved in CaSR Signalling
PLOS ONE | www.plosone.org 2 January 2014 | Volume 9 | Issue 1 | e85237
0.22 kV. After electroporation, TT cells were cultured in 24-well
clear bottom plates in complete F-12K medium for 72 hr, before
using them for further experiments.
To confirm efficient knock-down of RAMP1 expression, RNA
was extracted from the experimental and control transfected cells
using Trizol (Invitrogen) 72 hr after transfection and cDNA was
synthesized from equal amounts of RNA using high-capacity RNA
to cDNA kit (Applied biosystems). Gene expression was measured
using TaqmanH probes for quantitative PCR using the ABi
7900HT sequence detection system (Applied biosystems). The
cytoskeletal protein beta actin (Actb) was used as an endogenous
control for normalizing the expression of target genes. 22DCt
method was used for relative expression analysis.
Immunocytochemistry
TT cells were seeded on 15615 mm glass coverslips (Menzel-
Glaser). The cells were washed twice with PBS and fixed for
10 min at room temperature using 4% PFA (Sigma Aldrich), 48 hr
post transfection. Cells were incubated with 10% rabbit serum
(Vector labs) and 0.5% BSA (w/v) for 30 min at room
temperature. Following this, primary antibodies (RAMP1 sc-
8850- Santacruz biotech or Goat IgG- Vector labs) were incubated
overnight at 4uC in 1% rabbit serum with 0.5% BSA (w/v) in PBS
at 1:50 v/v dilution of the 0.2mg/ml stock concentration.
Coverslips were washed with 0.5% BSA (w/v) in PBS and then
incubated with secondary antibody (Rabbit anti goat IgG
conjugated with FITC, DAKO) for 45 min in dark at room
temperature in 1% rabbit serum with 0.5% BSA in PBS at 1:400
dilution of 2.5mg/ml stock concentration. Following the incubation,
Figure 1. Spatial localization of CaSR and RAMPs in COS-7 cells. (A) COS-7 cell transfected with CaSR-citrine alone showing intracellular
localisation of CaSR (red circle) in the absence of RAMP expression. (B) COS-7 cells co-transfected with RAMP-cerulean (left column) and CaSR-citrine
(column 2) were imaged by confocal microscopy 48 hr post transfection. 50 pixel dot ROI was manually drawn around the cell membrane of the
CaSR-citrine image to measure cell-surface FRET (column 3). Scale bar 10mm. Red arrows on the FRET images (right column) indicate areas of co-
localization between CaSR and RAMP on the cell-surface, which are shown magnified in the insets.
doi:10.1371/journal.pone.0085237.g001
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the coverslips were washed with 0.5% BSA (w/v) in PBS and
incubated with DAPI counterstain at 1:5000 dilution of 5 mg/ml
stock concentration for 3 min followed by further three washes
with 0.5% BSA (w/v) in PBS. The coverslips were drained to
remove excess liquid and mounted on a clean glass slide (VWR
international) using Prolong Gold (Invitrogen) and stored in dark
at room temperature overnight before imaging.
HCX PL FLUOTAR L 40.060.60 dry objective on an Inverted
widefield fluorescence microscope LeicaDMI4000B was used to
capture images at 8-bit resolution and 161 binning at room
temperature. Separate channels were set each for FITC (exposure
1.5 sec, gain 3.5, filter-L5), DAPI (exposure 150 ms, gain 3.0, filter
A4) to capture RAMP1 or control IgG staining and nuclear
staining respectively.
Western blotting
Sub confluent cultures of transiently transfected COS-7 cells or
TT cells were harvested using 2 mm glass beads in ice cold PBS.
The cells were then spun and lysed on ice using a Dounce
homogeniser, and the resulting lysate was spun at 40,000 g for 40
minutes at 4uC. The pellet containing membranes was then
resuspended in buffer containing 100 mM NaCl, 50 mM HEPES,
Figure 2. Cell-surface FRET efficiencies of CaSR+RAMPs and fraction of receptor components involved in FRET complex. (A) Cell-
surface FRET efficiencies of individual RAMPs with CaSR compared among themselves and also with respective negative control Citrine alone+RAMP-
Cerulean. Data are expressed as a percentage of a positive control comprising cells expressing a Citrine-Cerulean fusion protein. *** p,0.001 (2-way
ANOVA, Bonferroni post-test) ***p,0.001 (Kruskal-Wallis test, Dunn’s multiple comparison test) (B) and (C) Stoichiometric analysis of fraction of donor
RAMP (Fd) and acceptor CaSR (Fa) present in FRET complex on the cell-surface, respectively.* p,0.05 Mann Whitney test. The graph represents data
from three independent experiments.
doi:10.1371/journal.pone.0085237.g002
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5 mM MgCl2, adjusted to pH 7.4 with KOH [32]. For western
blots of COS-7 cells to determine the localization of CaSR
expression transfected with the different RAMPs, both total cell
lysates and membrane samples were analysed.
Immunoblotting was performed by separating the components
of 10–15mg of CaSR+RAMP transfected COS-7 or TT cell
membrane on 8% or 12% SDS-PAGE gel to probe for CaSR or
RAMP expression respectively. The gel was electrophoresed at
90 V and proteins were transferred to Hybond-P polyvinylidene
Table 1. Mean and SEM values of cell membrane FRET efficiency and fraction of receptor components involved in FRET between
the CaSR and RAMPs.
CaSR+RAMP
NFRET % of
positive control
Fraction of acceptor
CaSR Fa (%)
Fraction of donor
RAMP Fd(%) R
Calculated ratio
CaSR:RAMP
CaSR+RAMP1 a40.063.4*** vs b 58.467.1 16.0 61.4 0.660.09 2.19: 1
CaSR+RAMP2 b9.961.5 - - 0.5 60.11 -
CaSR+RAMP3 65.364.4 *** vs a,b 67.00610.0 26.064.3* 0.660.2 1.5: 1
Significant difference in the NFRET value was observed between CaSR+RAMP1 and 3 vs. CaSR+RAMP2, and between CaSR+RAMP1 vs. CaSR +RAMP3 (***p,0.0001,
Kruskal-Wallis test, Dunn’s multiple comparison test). Significant differences were also observed in the fraction of RAMP3 and RAMP1 donor (Fd) in cell-surface FRET
complex (*p,0.05, Mann Whitney test). There was no significant difference between fraction of CaSR acceptor in the FRET complex between RAMPs 1 and 3 (Fa). The
table displays combined data of three independent experiments.
doi:10.1371/journal.pone.0085237.t001
Figure 3. Cell surface expression of non-tagged CaSR. (A) Western blot of membrane and total cell lysate preparations from COS-7 cells
transfected with CaSR alone (lane 1), CaSR and RAMP1 (lane 2), and CaSR and RAMP3 (lane 3), incubated with antibody to the CaSR, demonstrating
the ability of RAMPs 1 and 3 to traffic the CaSR to the cell surface. (B) FACS analyses of non-permeabilised COS-7 cells expressing CaSR with either
RAMPs 1, 2 or 3 showing shift from the IgG control in number of cells with surface fluorescence in RAMP1 and RAMP3 expressing cells, but not
RAMP2 expressing cells.
doi:10.1371/journal.pone.0085237.g003
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chloride (PVDF) membrane (Amersham) at 100 V for 80 min.
Proteins of interest were detected by first incubating with primary
antibodies (RAMP1, sc-8850 Santacruz biotechnology 1/300 v/v
dilution from 0.2mg/ml stock concentration, the CaSR ab-19347,
Abcam was diluted 1/500 v/v from 1mg/ml stock concentration.)
overnight at 4uC, followed by a HRP conjugated secondary
antibody (anti goat or anti mouse HRP conjugated IgG
immunoglobulin, Sigma Aldrich at 1:10,000 dilution) for 1 hour.
Chemiluminescence was detected using detecting photographic
film (HyperfilmTM ECL, Amersham).
Intracellular calcium imaging
TT cells were seeded at a density of 100,000 cells per well in a
24-well clear-bottom plate (Costar, Corning) for two days before
intracellular calcium assays. Media were removed and cells were
washed twice with PBS and loaded for 45 min at 37uC with 500ml
of physiological salt solution (buffer) containing: (contents [mM]: 2
CaCl2, 100 NaCl, 5.4 KCl, 1.2 MgSO4, 5.5 Glucose, 6 NaHCO3,
1.2 Na2HPO4, 20 HEPES, pH 7.4), 5mM Fluo-4AM dye (5 mM
stock in DMSO) and 2.5 mM water soluble probenecid. After
incubation cells were washed three times with the buffer and
further incubated with 500ml of buffer containing 2 mM CaCl2 for
45 min at 37uC. During this incubation, the cells were treated with
antibodies (RAMP1 goat polyclonal antibody, sc-8850, Santacruz
biotech; Goat control IgG, Vector labs) according to the
requirement of the experiment. After 45 min, the buffer was
replaced with 360ml of physiological salt solution containing
1.5 mM CaCl2 when using Cinacalcet, or containing 2 mM
CaCl2, when using Neomycin as an agonist. The cells were imaged
using an HCX PL FLUOTAR 10.060.30 dry objective on an
Inverted wide field fluorescence microscope (Leica AF6000 Time
Lapse) at 37uC (single channel fluorescence image using the L5
filter, with exposure of 1 sec, at gain and intensity of 5). Images
were taken at 12-bit resolution at every 1.2 sec with first 35 frames
recorded as baseline after which 40ml of 10X solution of agonist
was added carefully and images were recorded for further 3 min.
Images from each well were exported in.tiff format and were
analysed using ImageJ software. A time-dependant response curve
was plotted using GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego California USA, www.graphpad.
com) and peak value of response for each cell was calculated using
AUC function. The peak value of response for each cell was then
calculated as percentage change from baseline fluorescence and
expressed in the graph as percentage above baseline.
Fluorescence-Activated Cell sorting (FACS)
COS-7 cells were transfected as mentioned before and 48 hr
later were washed with PBS, harvested using non-enzymatic
dissociation and fixed using 4% PFA for 15 min and resuspended
in FACS buffer (PBS, 1% FBS). Cells were then treated with 5%
Figure 4. Expression of CaSR and RAMP1 in TT cells. (A) mRNA expression levels of CaSR and RAMPs in control TT cells. (B) Representative
western blot showing protein expression of CaSR and RAMP1 in TT cell membranes. (C) Concentration-dependent Cinacalcet-induced increase in
intracellular calcium release in TT cells in presence of 1.5 mM CaCl2 (Ec50 50361.29 nM). The data are combined from three independent experiments
with a total of n = 50 cells analysed at -4.5, -5, -5.5, -6 and -11 M; 20 cells analysed at 26.5, 27, 27.5 and 28 M; and 30 cells analysed for 29 and
210 M concentrations. (D) Concentration-dependent Neomycin-induced response in presence of 2 mM CaCl2 (Ec50 9161.45 mM). The data are
combined from three independent experiments with a total of n = 43, 48, 45, 46, 88, 74, 23 and 29 cells analysed per concentration respectively,
going from high to low doses.
doi:10.1371/journal.pone.0085237.g004
RAMP1 Is Involved in CaSR Signalling
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e85237
FBS, washed and incubated with 1.2mg mouse CaSR antibody
(abcam, Cambridge, USA) per 106 cells for 1 hr at room
temperature, and subsequently with secondary antibody conju-
gated with FITC (DAKO, Carpinteria, USA) (1mg/106 cells) for
30 min. As negative controls cells were incubated with mouse IgG
control, as well as with the secondary antibody only. From each
sample, ten thousand cells were analysed using a flow cytometer
(FACSCalibur, Becton Dickinson, San Jose, CA) after excluding
cell debris.
Statistical analysis
All data shown are mean6 SEM. The graphs were plotted in
and the statistical analysis was performed using GraphPad Prism
version 5.00 for Windows (GraphPad Software, San Diego
California USA, www.graphpad.com). The statistical tests per-
formed for each specific experiment is shown in the relevant results
section. Normalcy test was performed on each set of data using
D’Agostino & Pearson omnibus normality test using Graphpad
prism 5 software. The precise number of cells and replicate
experiments is detailed in the relevant figure legends.
Results
Cell membrane FRET-based stoichiometric analysis of the
interaction of CaSR with RAMPs
The interaction of RAMPs with CaSR in transfected COS-7
cells was confirmed using FRET. Sensitized emission FRET was
used to compare the efficiency of interaction of RAMPs with
CaSR, and FRET-based stoichiometry to calculate the fractions of
RAMP and CaSR in the FRET complexes on the cell membrane.
As a negative control in order to measure the background levels of
FRET- a combination of Citrine only, along with different
RAMP-Cerulean constructs were used.
Figure 5. Effect of RAMP1 mRNA knockdown on TT cells. (A) mRNA expression levels of RAMP1, RAMP2 and CaSR in TT cells transfected with
RAMP1 or scrambled siRNA, 72 hr post-transfection expressed as fold change normalised to Actb. (B) Representative images from immunofluorescent
staining for RAMP1 expression in cells transfected with scrambled siRNA (top panel) and RAMP1 siRNA(bottom panel), 72 hr after transfection. (C)
Intracellular calcium response of the RAMP1 siRNA cells to 1mM Cinacalcet in presence of 1.5 mM CaCl2 and (D) 100mM Neomycin in presence of
2 mM CaCl2 The responses were decreased by,42% and,50% respectively compared to scrambled siRNA transfected cells. The data are combined
from five independent experiments with a total of 241, 231 and 154 cells analysed in (C), and 354, 354 and 118 cells analysed in (D) for knock-down,
control and normal conditions respectively. **** p,0.0001 analysed by two-tailed Mann-Whitney test.
doi:10.1371/journal.pone.0085237.g005
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When COS-7 cells were transfected with CaSR alone, majority
of the receptor was localized within the peri-nuclear region
(figure 1A). However, when either RAMP1-Cer or RAMP3-Cer
were co-transfected with the CaSR, distinct regions of co-
localization of FRET complexes were seen ranging from the
peri-nuclear region and cytoplasm, towards the cell membrane
(figure 1B). Red arrows on the FRET figures indicate cell-surface
FRET complexes of CaSR+RAMP1/3 (figure 1B and high power
insets). In case of RAMP2-Cerulean, co-localization with CaSR
could be seen in the perinuclear region only with no detectable
cell-surface co-localization (figure 1B).
Intensity values from the donor, acceptor and FRET images
were obtained from cell membrane regions using a series of 50
pixel-dots to define regions of interest (ROI) on the acceptor image
(figure 1B third column). Using these values, cell-surface NFRET
values and stoichiometric calculations were performed for the
CaSR (figure 2A,B and C and Table 1). The cell-surface NFRET
values for CaSR+RAMP1/3 combinations were significantly
higher than their corresponding negative controls, and CaSR+
RAMP2 cell-surface FRET complex (figure 2A; Table 1). NFRET
between CaSR and RAMP2 was not significantly different from
the corresponding negative control (RAMP2-Cerulean and Citrine
alone). CaSR+RAMP3 cell-surface FRET efficiency was found to
be significantly higher by ,1.6 fold compared to CaSR+RAMP1
(figure 2A, Table 1). As shown by the R value (ratio of total CaSR
to RAMP expression on the cell surface), there was an equal excess
of RAMP expression compared with CaSR in both CaSR+
RAMP1/3 transfected cells. Of this, the fraction of total RAMP1
that was at the cell surface, involved in cell-surface FRET complex
was 1661.4%, whereas for RAMP3 the proportion on the surface
was 26.064.3% (figure 2B and Table 1). So the fraction of
RAMP3 on the cell surface was ,1.6 fold higher than RAMP1 in
FRET complex with CaSR, which was significant. The fraction of
CaSR present in the FRET complex on the cell-surface was
58.467.1% (with RAMP1) and 67.00610.0% (with RAMP3)
(figure 2C and Table 1); out of its total population. There was no
statistically significant difference between the fraction of CaSR in
RAMP1 and RAMP3 cell-surface FRET complexes. This means
that both RAMP1 and 3 exhibited equal efficiencies in trafficking
CaSR to the cell surface, however there was a higher fraction of
RAMP3 (donor) in the FRET complex on the cell surface,
consequently causing an increased FRET efficiency, compared to
RAMP1.
Cell surface expression of non-tagged CaSR
In membrane preparations from COS-7 cells expressing CaSR
alone, no CaSR protein could be detected by western blotting
(figure 3A, lane 1). In contrast, when CaSR was expressed with
either RAMP1 or RAMP3, in the western blots, there were clear
bands between 140 and 200 kDa corresponding with the predicted
size of the CaSR (Figure 3A, lanes 2 and 3 respectively). As a
control, CaSR was detected in all the three conditions in samples
prepared from COS-7 cell lysates, indicating total protein
expression.
We confirmed these results using FACS on the same (non-
permeabilised) COS-7 cells. In cells expressing the CaSR with
RAMP1, we measured clearly increased levels of surface
fluorescence compared with binding of isotype control antibodies,
indicating RAMP1-mediated cell surface expression of CaSR
(figure 3B left panel). In cells expressing CaSR and RAMP2,
which we know from the FRET studies to not be an effective
trafficking partner, there was no shift with CaSR compared with
isotype control antibodies, indicating no surface expression
(figure 3B, centre panel). In cells expressing CaSR and RAMP3,
we observed surface expression greater than the isotype controls
(figure 3B right panel), and greater than in cells expressing CaSR
with RAMP1.
Attenuation of CaSR signalling by modulation of RAMP1
expression in TT cells
To explore the role of RAMP1 in CaSR signalling, we used TT
cells that express mRNA and protein endogenously for CaSR,
RAMP1 and RAMP2 but not RAMP3 (figure 4A and 4B). To
confirm the functional activity of the CaSR in TT cells, increases
in the intracellular calcium levels were measured using live cell
imaging. We obtained concentration-response curves for the
allosteric modulator of the CaSR, Cinacalcet in presence of
1.5 mM CaCl2 (Ec50 50361.29 nM), and the agonist Neomycin in
presence of 2 mM CaCl2 (Ec50 9161.45 mM) (figure 4C and 4D)
by recording images for , 3.5 min at every concentration.
The functional responses to Cinacalcet were compared between
TT cells, whose RAMP1 expression had been attenuated using
siRNA and controls, transfected with an appropriate scrambled
sequence. 72 hr after transfection, significant decrease in mRNA
(by ,80%) and protein expression levels of RAMP1 were
observed in RAMP1 siRNA-transfected TT cells compared to
the scrambled control (Figure 5A and B respectively). There was
no effect of RAMP1 or scrambled siRNA transfection on the
mRNA expression levels of RAMP2 or CaSR (Figure 5A). TT
cells transfected with RAMP1 or control scrambled siRNA were
treated with 1mM Cinacalcet in presence of 1.5 mM CaCl2 or
100mM Neomycin in presence of 2 mM CaCl2 and signalling was
quantified by measuring increase in intracellular calcium using a
live cell imaging system. The response to 1mM Cinacalcet was
significantly attenuated by ,42% in RAMP1 siRNA-transfected
cells compared to the negative control (figure 5C). There was no
difference between the signalling of the negative control and
control non-transfected TT cells, excluding non-specific effects
due to transfection. 100mM Neomycin, induced ,50% less
elevation in the intracellular calcium release in RAMP1 siRNA-
transfected cells compared with both scrambled transfected and
native controls (figure 5D).
Attenuation in CaSR signalling by RAMP1 antibody in TT
cells
TT cells were treated with a characterised commercial RAMP1
polyclonal antibody [33–35], which induced a concentration-
dependent attenuation of intracellular calcium release in response
to 1mM Cinacalcet in presence of 1.5 mM CaCl2 (figure 6A). The
response to 1mM Cinacalcet was significantly attenuated by
0.0125mg/ml and 0.025mg/ml dose of RAMP1 antibody by 35%
and 57% respectively (both p,0.001). The differences between the
effect of 0.0125mg/ml and 0.025mg/ml RAMP1 antibody (21%) was
statistically significant (p,0.01). It was also observed that
0.025mg/ml RAMP1 antibody reduced 100mM Neomycin re-
sponse in presence of 2 mM CaCl2, significantly by ,48%
compared to Control IgG (p,0.001) (figure 4B).
Discussion
RAMPs are promiscuous proteins that are shown to engender
different receptor phenotypes to a few family B GPCRs
[25,27,28,36]. It was discovered that the association of the CaSR
with RAMP 1 or 3 is essential for its cell-surface trafficking in
transfected cells [23,24]. In order to investigate further the
consequences of this interaction, we hypothesized that RAMPs
associate with the CaSR to form higher-order oligomeric
complexes, and play a role in signalling of the CaSR. Particularly,
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this study has characterized additional functions of RAMP1 in
complex with the CaSR, implying a two-tier regulation which
comprises cell surface trafficking and signalling of the CaSR.
In this study we have used a series of well-established techniques
to confirm and extend previous work in the area using transfected
cells, and to determine the relevance of those findings in a more
physiological setting of a cancer cell line. The FRET techniques
we have used differ from established techniques only in our use of
a membrane region of interest to compare total and cell surface
interactions. This very simple analysis of FRET data could be
useful in other research where proteins are trafficked to the cell
surface from inside the cell. Our studies increase knowledge of the
RAMP/CaSR interactions because we have analysed the
stoichiometric relationships between the proteins involved, some-
thing which was not performed in earlier studies using tagged
constructs. It should be emphasised that our results were obtained
only by FRET, a recognised method to determine protein-protein
interactions. Further confirmatory studies using different methods
such as co-immunoprecipitation in both over-expressing and
native cells could be used to provide additional support for our
findings. Such techniques may have the ability to reveal shifts in
the proportion of oligomers, dimers and monomers.
It could be suggested that the fluorophore-protein constructs
may not behave identically to native proteins. However, we show
using cells expressing untagged receptor constructs, that RAMPs 1
and 3 but not 2 are required for cell surface expression of the
receptor by FACS and western blotting. In addition, FRET is well
established, and our data are entirely consistent with studies using
a different technique to show interactions of RAMPs 1&3 but not
RAMP2 with the CaSR [23]. The other techniques we have used
are well-established. Knockdown siRNA sequences are those used
by others [23], and we demonstrate their effectiveness in reducing
mRNA and protein expression. The effects of the knockdown and
antibody treatments are disclosed using a well-established readout
of elevation of intracellular calcium after treatment with pharma-
cological ligands.
FRET-based stoichiometric analysis in this study indicated that
a unit of CaSR-complex on the cell surface with either RAMP
consist of ,1.6 times more RAMP3 than RAMP1. Recently the
presence of high order oligomers of other GPCRs at cell surface
has been reported [37-39]. However, it still remains to be
understood how many units of CaSR and RAMPs heteromerize to
form larger oligomeric complexes on the cell membrane. It is
possible that such large oligomers could contain different RAMPs
with the CaSR, but the complete functional consequences of such
complex heteromeric structures are not understood yet. An
additional level of regulation could be provided by the PDZ-
binding motif which is present on RAMP3 [40], which can have
effects on recycling and internalization of the CaSR, as already
reported in the case of the adrenomedullin receptor-2
(CLR+RAMP3) [40,41].
The demonstration that knockdown of RAMP1 expression
attenuates CaSR signalling could be due to a decreased population
of CaSR+RAMP1 complexes at the cell-surface. However, the
ability of antibodies to attenuate the ability of CaSR ligands to
induce elevation of intracellular calcium release points to an
additional more complex role for RAMPs in CaSR signalling.
There are several potential mechanisms for this. The physical
presence of the antibody bound to the RAMP1 part of the
RAMP1/CaSR complex could prevent normal ligand binding.
Alternatively, the antibody may interfere with the interaction
between the RAMP and CaSR so that they no longer form a
functional heteromer. A third possibility is that antibody bound to
the RAMP1 may affect the internalisation of the receptor complex
to reduce the presence of functional receptor heteromers on the
cell surface. It is also conceivable that antibody induces
conformational changes in the receptor that normally follow
ligand binding or coupling to the G-proteins of the CaSR so as to
alter downstream signalling. It is unlikely, though still possible, that
RAMP1 is directly involved in the formation of the ligand binding
pocket, since the sites for binding of Ca2+ [42] (ECD), neomycin
(ECD) [43], and the calcimimetic Cinacalcet (TM domain)
[44,45], have been mapped on the CaSR itself.
Figure 6. Attenuation of CaSR response in TT cells by RAMP1 antibodies. (A) Concentration-dependant decrease in Cinacalcet-induced
intracellular calcium release in presence of 1.5 mM CaCl2, by RAMP1 antibodies in TT cells. Total cells analysed combined from five independent
experiments are 272 (1mM Cinacalcet), 261 (0.0125mg/ml control IgG), 240 (0.025mg/ml control IgG), 252 (0.0025mg/ml RAMP1 Ab), 272 (0.0125mg/ml
RAMP1 Ab) and 250 (0.025mg/ml RAMP1 Ab). (B) 0.025mg/ml RAMP1 antibody caused a significant inhibition of 100mM Neomycin response in presence
of 2 mM CaCl2 compared to control IgG. Total cells analysed combined from five independent experiments are 192 (100mM Neomycin), 177 (0.025mg/
ml control IgG) and 166 (0.025mg/ml RAMP1 Ab). *** p,0.001 determined by Kruskal-Wallis test, Dunn’s multiple comparison post-test, ** p,0.01 two-
tailed Mann-Whitney test.
doi:10.1371/journal.pone.0085237.g006
RAMP1 Is Involved in CaSR Signalling
PLOS ONE | www.plosone.org 9 January 2014 | Volume 9 | Issue 1 | e85237
The physiological relevance of the findings remain to be
confirmed in detail, and studies in cells from a range of species,
and to measure calcitonin secretion in cells with altered RAMP
expression would be valuable. The development of tissue-specific
knockout mice for the RAMPs will also provide opportunities for
greater insight into their roles in calcium homeostasis specifically
and endocrinology generally.
In conclusion, this study has provided novel insights into the
interaction of CaSR and RAMPs which point towards the
presence of a higher oligomeric receptor-complex, with the
possibility of more than one RAMP molecule per CaSR. Secondly,
RAMP1 is essential for the cell surface trafficking of the CaSR in
endogenously expressing cells. Finally, RAMP1 plays a role in the
signalling of CaSR in TT cells that are at the cell surface, by an
unknown mechanism. Therapeutic targeting of RAMP1 may be a
method to modulate calcium homeostasis via the CaSR.
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